Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice

There is considerable interest in expanding B cell-targeted therapies in human autoimmune diseases. However, clinical trials in human primary biliary cholangitis (PBC) using a chimeric antibody against human CD20 (hCD20) have showed limited efficacy. Two potential explanations for these disappointin...

Descripción completa

Detalles Bibliográficos
Autores principales: Moritoki, Yuki, Tsuneyama, Koichi, Nakamura, Yuka, Kikuchi, Kentaro, Shiota, Akira, Ohsugi, Yoshiyuki, Lian, Zhe-Xiong, Zhang, Weici, Yang, Guo-Xiang, Ueki, Shigeharu, Takeda, Masahide, Omokawa, Ayumi, Saga, Tomoo, Saga, Akiko, Watanabe, Daisuke, Miura, Masahito, Ueno, Yoshiyuki, Leung, Patrick S. C., Tanaka, Atsushi, Gershwin, M. Eric, Hirokawa, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224429/
https://www.ncbi.nlm.nih.gov/pubmed/30450101
http://dx.doi.org/10.3389/fimmu.2018.02534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224429/
https://www.ncbi.nlm.nih.gov/pubmed/30450101
http://dx.doi.org/10.3389/fimmu.2018.02534

Ejemplares similares